Prime Medicine (PRME) furnishes new corporate presentation for investors

Rhea-AI Filing Summary

Prime Medicine, Inc. furnished an updated corporate presentation on its investor website, with the materials attached as Exhibit 99.1. The presentation, dated January 2026, is provided under a Regulation FD disclosure to share information with the market in a broadly accessible way. The company states that this information is being furnished rather than filed, which means it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities law filings unless specifically referenced.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001894562false00018945622026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

FORM 8-K

___________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

January 12, 2026

Date of Report (date of earliest event reported)

___________________________________

Prime Medicine, Inc.

(Exact name of registrant as specified in its charter)

___________________________________

Delaware (State or other jurisdiction of incorporation)			001-41536 (Commission File Number)			84-3097762 (I.R.S. Employer Identification No.)
60 First Street Cambridge, MA 02141
(Address of principal executive offices and zip code)
(617) 465-0013
(Registrant's telephone number, including area code)

___________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common stock, par value $.00001 per share

PRME

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§250.12b-2 of this chapter).

Emerging growth company    ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On January 12, 2026, Prime Medicine, Inc. (the "Company") posted an updated corporate presentation to its website at https://investors.primemedicine.com/news-events. A copy of the corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference. Reference to the Company’s website is for inactive textual reference only and the content of the website should not be deemed incorporated by reference into this Current Report on Form 8-K.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 - Financial Statements and Exhibits

(d) Exhibits

Exhibit Number						Description
99.1						Corporate Presentation, dated January 2026
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 12, 2026

Prime Medicine, Inc.
By:			/s/ Allan Reine
Name:			Allan Reine, M.D.
Title:			Chief Executive Officer

FAQ

What did Prime Medicine, Inc. (PRME) disclose in this 8-K?

Prime Medicine, Inc. reported that it posted an updated corporate presentation to its investor website and furnished the same materials as Exhibit 99.1 under a Regulation FD disclosure.

Where can investors access the new Prime Medicine (PRME) corporate presentation?

Investors can access the updated corporate presentation on Prime Medicine’s website at https://investors.primemedicine.com/news-events, and it is also furnished as Exhibit 99.1.

Is the Prime Medicine (PRME) corporate presentation considered filed with the SEC?

The company specifies that the information in Item 7.01, including Exhibit 99.1, is being furnished and not deemed filed for purposes of Section 18 of the Exchange Act.

Can the Prime Medicine (PRME) presentation be incorporated into other SEC filings?

The company notes that the presentation will not be incorporated by reference into other Securities Act or Exchange Act filings unless it is expressly set forth by specific reference in such a filing.

Who signed the Prime Medicine (PRME) 8-K related to the corporate presentation?

The report was signed on behalf of Prime Medicine, Inc. by Allan Reine, M.D., who is identified as the Chief Executive Officer.

What exhibits were included with this Prime Medicine (PRME) 8-K?

The 8-K includes Exhibit 99.1, the corporate presentation dated January 2026, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.